ELENA GARRALDA


Current positions


Academic Qualifications

  • Medical Doctor’s Degree. Universidad Autónoma de Madrid, Madrid. 2005.
  • Medical Oncology Specialization. Hospital Universitario 12 de Octubre, Madrid. 2011.
  • Master’s Degree in Molecular Oncology. Centro de Estudios Biosanitarios (CEB), Madrid. 2013.
  • Management Fundamentals and Skills for Scientists and Researchers. IE Business School, Madrid. 2013.
  • ECFMG Certification – Educational Commission for Foreign Medical Graduates. USA, 2012.
  • DEA, Advanced Studies Diploma. Universidad Complutense de Madrid, Madrid. 2010.
  • Joint ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research (Flims), Switzerland. 2013.

Areas of Research

  • Targeted Agents
  • Early Drug Development
  • Translational Research
  • Immunotherapy

Mainly focused on proof-of-concept and proof-of-mechanism trials with targeted therapies with special emphasis on those in cell signaling, cancer stem cells, and immuno-oncology as well as epigenetics.

First-in-human studies of targeted therapies, rational combinations of targeted therapies, biomarker-driven trials, and trials in molecularly selected populations.

Linking clinical research at VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) “la Caixa” with the different areas of investigation carried out at our Institute such as the molecular analysis of patients’ tumors and molecular prescreening, as well as developing novel diagnostic tests (e.g. circulating DNA; Nanostring) with marketable pathways to select the best anti-cancer therapy or drug-drug combinations – covering some of the most promising targets in immune checkpoints and cytokines -matched to the aberrations of individual tumors.

Converging immuno-oncology and genomics to further advance precision medicine against cancer, and aim at expanding research in epigenetics


Research projects

  • Co-evolutionary dynamics landscape of neoplasic cells and T-cells interaction during cancer immunotherapy, Swiss Bridge Foundation.
  • BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology – CAIMI, Fundación BBVA.
  • Plataforma Tecnológica de VHIO para Estudiar la Evolución Clonal y la Resistencia al Tratamiento Inmune y Tratamientos Dirigidos en Cáncer, Novartis Farmacéutica.
  • Clinical Study “Basket of Basket”, MO39164, F. Hoffman-La Roche, Ltd.
  • Identificación y Caracterización de Nuevos Elementos Reguladores durante la Adquisición de Competencias Metastásicas en un Modelo de EMT y en Tumores de Mama Triple Negativo, Instituto de salud Carlos III.
  • Personalized Non-Invasive T-cell Therapies Targeting the Mutanome. GOI 2017.
  • Biomarkers of Cancer-Related Cachexia in Human Plasma Proteome. FIS PI10/02072.
  • Personalized Treatment of Colon Cancer Patients Guided by Genomic Expression Profile of Tumor Samples. MSPSI 2012.

Scientific Committees & Advisory Roles

  • ESMO – Women for Oncology. Committee Member. 2017.
  • Evaluation Committee – CLIPP Labellisation 2019-2024, Institut National de Cancer, Paris. 2018.
  • Comité Evaluador IDEA2 Madrid, MIT (Massachusetts Institute of Technology) – M+Vision Consortium. 2015.
  • Partners of Choice Joint Network Committee, MedImmune, Maryland. 2018.
  • imCORE – Immunotherapy Centres of Research Excellence Network Translational Committee, Roche. 2017. • Member of the Cancer Core Europe Consortium (CCE). 2017.
  • ESMO Drug Developmental Therapeutics – Committee Member. Since 2018.
    • Reviewer for Annals of Oncology, ESMO.
    • Reviewer for Cancer Treatment Reviews, Elsevier.
    • Reviewer for British Journal of Cancer, BJC Editorial Office.

Prizes and Scholarships

  • TxSCO – Fellows Abstract Award, Texas Society of Clinical Oncology. 2013.

Most relevant scientific publications

  • Garralda E, Dienstmann R, Piris A, Braña I, Rodon J, Tabernero J. New clinical trial designs in the era of Precision Medicine. Mol Oncol. 2019 Mar;13(3):549-557
  • Hierro C, Matos I, Martin-Liberal J, Ochoa de Olza M, Garralda E.Agnostic-Histology Approval of new drugs in Oncology: are we already there? Clin Cancer Res. 2019 Jan 22. pii: clincanres.3694.2018. doi: 10.1158/1078-0432.CCR-18-3694. [Epub ahead of print]
  • Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A. A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.  Clin Cancer Res. 2019 Jan 15;25(2):496-505. doi: 10.1158/1078-0432.CCR-18-2014. Epub 2018 Oct 16. PubMed PMID: 30327308.
  • Blanca Homet Moreno, Elena Garralda, Ricardo Hitt.Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas,Clinical & translational Oncology, Educational Series 2010: 12; 468-472. DOI 10.1007/s12094-010-0539-z
  • J. Sepulveda and E. Garralda. Neuro-oncology Diagnostic and Treatment Guide. Chapter 2.1: Meningealcarcinomatosis. Pages 83-92. ISNB: 978-84-694-8523-I.
  • Banerjee S, Dafni U, Allen T, Arnold D, Curigliano G M.D, Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. ESMO Open. 2018 Sep 21;3(6):e000422. doi: 10.1136/esmoopen-2018-000422. eCollection 2018. PubMed PMID: 30273420; PubMed Central PMCID: PMC6157518.
  • Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, Curigliano G M.D, Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourti Z, Zygoura P, Peters S. Report on the status of women occupying leadership roles in oncology. ESMO Open. 2018 Sep 21;3(6):e000423. doi: 10.1136/esmoopen-2018-000423. eCollection 2018. PubMed PMID: 30273418; PubMed Central PMCID: PMC6157529.
  • Cubillo A, Álvarez-Gallego R, Muñoz M, Pond G, Perea S, Sánchez G, Martin M, Rodríguez-Pascual J, Garralda E, Vega E, de Vicente E, Quijano Y, Muñoz C, Ugidos L, Toledo RA, Hidalgo M. Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer. Am J Clin Oncol. 2019 Jan;42(1):56-59. doi: 10.1097/COC.0000000000000474. PubMed PMID: 29975196.
  • Ochoa de Olza M, Oliva M, Hierro C, Matos I, Martin-Liberal J, Garralda E. Early-drug development in the era of immuno-oncology: are we ready to face the challenges? Ann Oncol. 2018 Aug 1;29(8):1727-1740. doi: 10.1093/annonc/mdy225. PubMed PMID: 29945232.
  • Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L,  Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 Jul;8(7):836-849. doi: 10.1158/2159-8290.CD-18-0338. Epub 2018 Apr 15. PubMed PMID: 29657135.
  • Toledo RA, Garralda E, Mitsi M, Pons T, Monsech J, Vega E, Otero Á, Albarran MI, Baños N, Durán Y, Bonilla V, Sarno F, Camacho-Artacho M, Sanchez-Perez T, Perea S, Álvarez R, De Martino A, Lietha D, Blanco-Aparicio C, Cubillo A, Domínguez O, Martínez-Torrecuadrada JL, Hidalgo M. Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. Clin Cancer Res. 2018 Aug 1;24(15):3550-3559. doi: 10.1158/1078-0432.CCR-18-0103. Epub 2018 Mar 27. PubMed  PMID: 29588308.
  • Hidalgo M, Martinez-Garcia M, Le Tourneau C, Massard C, Garralda E, Boni V, Taus A, Albanell J, Sablin MP, Alt M, Bahleda R, Varga A, Boetsch C, Franjkovic I, Heil F, Lahr A, Lechner K, Morel A, Nayak T, Rossomanno S, Smart K, Stubenrauch K, Krieter O. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Ap 1;24(7):1536-1545. doi: 10.1158/1078-0432.CCR-17-1588. Epub 2017 Dec 7. PubMed PMID: 29217526.
  • Garralda E, Dienstmann R, Tabernero J. Pharmacokinetic/Pharmacodynamic Modeling for Drug Development in Oncology. Am Soc Clin Oncol Educ Book. 2017;37:210-215. doi: 10.14694/EDBK_180460. Review. PubMed PMID: 28561730.
  • Toledo RA, Cubillo A, Vega E, Garralda E, Alvarez R, de la Varga LU, Pascual  JR, Sánchez G, Sarno F, Prieto SH, Perea S, Lopéz-Casas PP, López-Ríos F, Hidalgo M. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab. Oncotarget. 2017 May 23;8(21):35289-35300. doi: 10.18632/oncotarget.13311. PubMed PMID: 27852040; PubMed Central PMCID: PMC5471055.
  • Toledo RA, Hatakana R, Lourenço DM Jr, Lindsey SC, Camacho CP, Almeida M, Lima JV Jr, Sekiya T, Garralda E, Naslavsky MS, Yamamoto GL, Lazar M, Meirelles O, Sobreira TJ, Lebrao ML, Duarte YA, Blangero J, Zatz M, Cerutti JM, Maciel RM,  Toledo SP. Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility. Endocr Relat Cancer. 2015 Feb;22(1):65-76. doi: 10.1530/ERC-14-0491. Epub 2014 Nov 25. PubMed PMID: 25425582; PubMed Central PMCID: PMC4289937.
  • Garralda E, Paz K, López-Casas PP, Jones S, Katz A, Kann LM, López-Rios F, Sarno F, Al-Shahrour F, Vasquez D, Bruckheimer E, Angiuoli SV, Calles A, Diaz LA, Velculescu VE, Valencia A, Sidransky D, Hidalgo M. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment. Clin Cancer Res. 2014 May 1;20(9):2476-84. doi: 10.1158/1078-0432.CCR-13-3047. Epub 2014 Mar 14. PubMed PMID: 24634382; PubMed Central PMCID: PMC4322867.
  • Gomez-Martin C, Plaza JC, Pazo-Cid R, Salud A, Pons F, Fonseca P, Leon A, Alsina M, Visa L, Rivera F, Galan MC, Del Valle E, Vilardell F, Iglesias M, Fernandez S, Landolfi S, Cuatrecasas M, Mayorga M, Jose Paulés M, Sanz-Moncasi P, Montagut C, Garralda E, Rojo F, Hidalgo M, Lopez-Rios F. Level of HER2 gene amplification predicts response and overall survival in HER2-positive Advanced gastric cancer treated with trastuzumab. J Clin Oncol. 2013 Dec 10;31(35):4445-52. doi: 10.1200/JCO.2013.48.9070. Epub 2013 Oct 14. PubMed PMID: 24127447.
  • Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera  P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4. PubMed PMID: 23466307.
  • Gómez-Martin C, Garralda E, Echarri MJ, Ballesteros A, Arcediano A, Rodríguez-Peralto JL, Hidalgo M, López-Ríos F. HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. J Clin Pathol. 2012 Aug;65(8):751-7. doi: 10.1136/jclinpath-2012-200774.  Epub 2012 May 8. PubMed PMID: 22569536; PubMed Central PMCID: PMC3410298.
  • Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012 Jan;18(1):45-52. doi: 10.1002/lt.22434. PubMed PMID: 21932373.